医院获得性肺炎4种治疗方案的成本-效果分析

Evaluation on Pharmacoeconomic Effectiveness of Four Therapeutic Schemes for Nosocomial Pulmonary Infections

目的评价医院获得性肺炎4种治疗方案的药物经济学效果。方法采用成本-效果分析法对4种治疗方案进行分析。结果头孢曲松、亚胺培南的成本-效果比相差不大;与头孢呋辛与庆大霉素联合用药比较,头孢曲松成本较低,而亚胺培南治愈率及总有效率最高;哌拉西林与阿米卡星联合用药的成本较低,有效率与总治愈率也较低。结论药物经济学在优化治疗方案、指导合理用药、提高经济效益方面具有重要作用。

Objective To evaluate the pharmacoeconomic effectiveness of four therapeutic schemes. Methods The therapeutic schemes for nosocomial pulmonary infections were analysed by cost- effectiveness analysis. Results The cost- effectiveness ratio of ceftriaxone and iminpenem was lower than that of cefuroxime and gentamycin. The cost of ceftriaxone was low and imipenem had the highest curative rate and total effective rate. The cost- effectiveness ratio of piperacillin and amikacin was the lowest, but their curative rate and effective rate were the lowest too. Conclusion Pharmacoeconomics plays an important role in optimizing therapeutic scheme, guiding use of drug and rising the economic benefit.